Beijing Hotgen Biotech Co Ltd Cash Flow Conversion Efficiency
Beijing Hotgen Biotech Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Beijing Hotgen Biotech Co Ltd (688068) has a cash flow conversion efficiency ratio of 0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥3.05 Million ≈ $446.80K USD) by net assets (CN¥2.93 Billion ≈ $428.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Beijing Hotgen Biotech Co Ltd (2016–2024)
Cash flow conversion efficiency of Beijing Hotgen Biotech Co Ltd from 2016 to 2024. This chart illustrates how Beijing Hotgen Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Beijing Hotgen Biotech Co Ltd for real-time trading data and today's change.
Beijing Hotgen Biotech Co Ltd Cash Flow Conversion Ratio Explained
Beijing Hotgen Biotech Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Beijing Hotgen Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing Hotgen Biotech Co Ltd ranked by their cash flow conversion efficiency. Also see Beijing Hotgen Biotech Co Ltd stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dynamatic Technologies Limited
NSE:DYNAMATECH
|
0.068x |
|
Beijing Kingee Culture Development Co Ltd
SHE:002721
|
0.000x |
|
Guangzhou Guangri Stock Co Ltd
SHG:600894
|
0.021x |
|
Isracard Ltd
TA:ISCD
|
0.323x |
|
Shaanxi Heimao Coking Co Ltd
SHG:601015
|
0.086x |
|
GCI Liberty, Inc.
NASDAQ:GLIBK
|
0.049x |
|
Sify Technologies Limited
NASDAQ:SIFY
|
0.002x |
|
Amata Corporation Public Company Limited
BK:AMATA
|
0.047x |
Annual Cash Flow Conversion Efficiency for Beijing Hotgen Biotech Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Beijing Hotgen Biotech Co Ltd from 2016 to 2024. Review how much free cash does Beijing Hotgen Biotech Co Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.07 Billion ≈ $449.84 Million |
CN¥-37.16 Million ≈ $-5.44 Million |
-0.012x | -59.91% |
| 2023-12-31 | CN¥3.36 Billion ≈ $491.39 Million |
CN¥-25.39 Million ≈ $-3.71 Million |
-0.008x | -102.59% |
| 2022-12-31 | CN¥3.35 Billion ≈ $490.75 Million |
CN¥978.75 Million ≈ $143.22 Million |
0.292x | -68.28% |
| 2021-12-31 | CN¥2.87 Billion ≈ $420.53 Million |
CN¥2.64 Billion ≈ $386.97 Million |
0.920x | +317.43% |
| 2020-12-31 | CN¥746.79 Million ≈ $109.28 Million |
CN¥164.62 Million ≈ $24.09 Million |
0.220x | +638.85% |
| 2019-12-31 | CN¥649.30 Million ≈ $95.01 Million |
CN¥19.37 Million ≈ $2.83 Million |
0.030x | -88.59% |
| 2018-12-31 | CN¥210.44 Million ≈ $30.79 Million |
CN¥55.04 Million ≈ $8.05 Million |
0.262x | +84.21% |
| 2017-12-31 | CN¥161.65 Million ≈ $23.65 Million |
CN¥22.95 Million ≈ $3.36 Million |
0.142x | -59.17% |
| 2016-12-31 | CN¥130.98 Million ≈ $19.17 Million |
CN¥45.54 Million ≈ $6.66 Million |
0.348x | -- |
About Beijing Hotgen Biotech Co Ltd
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers public safety solutions such as drug tasting, customs disease control, bioterrorism and food safety solutions. The company also provides clinical diagnostics and product solutions, inclu… Read more